Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity

Immunity. 2023 Feb 14;56(2):320-335.e9. doi: 10.1016/j.immuni.2022.12.017. Epub 2023 Jan 23.

Abstract

Neuronal signals have emerged as pivotal regulators of group 2 innate lymphoid cells (ILC2s) that regulate tissue homeostasis and allergic inflammation. The molecular pathways underlying the neuronal regulation of ILC2 responses in lungs remain to be fully elucidated. Here, we found that the abundance of neurotransmitter dopamine was negatively correlated with circulating ILC2 numbers and positively associated with pulmonary function in humans. Dopamine potently suppressed lung ILC2 responses in a DRD1-receptor-dependent manner. Genetic deletion of Drd1 or local ablation of dopaminergic neurons augmented ILC2 responses and allergic lung inflammation. Transcriptome and metabolic analyses revealed that dopamine impaired the mitochondrial oxidative phosphorylation (OXPHOS) pathway in ILC2s. Augmentation of OXPHOS activity with oltipraz antagonized the inhibitory effect of dopamine. Local administration of dopamine alleviated allergen-induced ILC2 responses and airway inflammation. These findings demonstrate that dopamine represents an inhibitory regulator of ILC2 responses in allergic airway inflammation.

Keywords: DRD1; allergic airway inflammation; dopamine; group 2 innate lymphoid cells; neuroimmune interaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dopamine / metabolism
  • Humans
  • Immunity, Innate*
  • Inflammation / metabolism
  • Interleukin-33 / metabolism
  • Lung / metabolism
  • Lymphocytes
  • Pneumonia* / metabolism

Substances

  • Dopamine
  • Interleukin-33